J Liver Cancer Search


Journal of the Korean Liver Cancer Study 2009;9(1):17-23.
Published online June 30, 2009.
New Treatment Response Evaluation Criteria and Current Therapeutics for Hepatocellular Carcinoma
Hyung Joon Yim
Department of Internal Medicine, Korea University Medical College, Ansan, Korea
Correspondence:  Hyung Joon Yim,
Email: gudwns21@medimail.co.kr
Copyright ©2009 by The Korean Liver Cancer Association
There has been no proven effective therapy in the setting of advanced HCC (hepatocellular carcinoma) according to BCLC (Barcelona Clinic Liver Cancer). Targeted therapy opened a new era in this subset of patients. Although sorafenib showed survival benefit, objective tumor response is uncommon, while systemic chemotherapies sometimes show partial tumor response without statistically significant survival benefits. These findings suggest evaluation of treatment response should not depend on conventional treatment response evaluation criteria. Overall survival is now considered to be the most important endpoint and time to disease progression can be secondary endpoint. Time to recurrence is the primary endpoint after the curative therapy. Currently, targeted therapy in addition to known curative or palliative therapy is now under investigation for synergistic effects, and new therapeutic agents are under development. Such advancement in the treatment of HCC will certainly have a great impact on patients’ survival in the near future.
Key Words: Hepatocellular carcinoma; Targeted therapy; Response; Survival

Editorial Office
1521 Gangnam Finance Plaza (FASTFIVE), 419 Teheran-ro, Gangnam-gu, Seoul 06160, Korea
Tel: +82-2-313-1900    E-mail: liver@klcsg.or.kr                

Copyright © 2022 by The Korean Liver Cancer Association.

Developed in M2PI

Close layer
prev next